Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$1,117 Mln
Revenue (TTM)
$191 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.4 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.2
Industry P/E
44.78
EV/EBITDA
-12.8
Div. Yield
0 %
Debt to Equity
0.5
Book Value
$--
EPS
$-1.4
Face value
--
Shares outstanding
40,632,100
CFO
$-222.16 Mln
EBITDA
$-268.64 Mln
Net Profit
$-327.59 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Silk Road Medical (SILK)
| 124.0 | 0.9 | 2.2 | 71.4 | -21.0 | -3.8 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|
|
Silk Road Medical (SILK)
| -76.8 | 24.0 | -32.3 | 56.0 |
|
S&P Small-Cap 600
| 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Silk Road Medical, Inc operates as a medical device company in the United States. The company offers various products for the treatment of carotid artery disease called transcarotid artery revascularization (TCAR). Its products comprise ENROUTE... Transcarotid Neuroprotection System that is used to directly access the common carotid artery and establish temporary blood flow reversal; ENROUTE Transcarotid Stent System for transcarotid access; ENHANCE Transcarotid Peripheral Access Kit, which is used to gain initial access to the common carotid artery; ENROUTE 0.014 Guidewire for atraumatic vessel navigation and target lesion crossing for delivery of interventional devices; and ENROUTE Enflate Transcarotid RX Balloon Dilation Catheter, a transcarotid rapid exchange balloon for the TCAR procedure. The company was incorporated in 2007 and is headquartered in Sunnyvale, California. As of September 17, 2024, Silk Road Medical, Inc operates as a subsidiary of Boston Scientific Corporation. Read more
CFO & COO
Mr. Lucas W. Buchanan
CFO & COO
Mr. Lucas W. Buchanan
Headquarters
Sunnyvale, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Silk Road Medical Inc (SILK) is $27.49 (NASDAQ) as of 26-Sep-2024 09:30 EDT. Silk Road Medical Inc (SILK) has given a return of -20.97% in the last 3 years.
Since, TTM earnings of Silk Road Medical Inc (SILK) is negative, P/E ratio is not available.
The P/B ratio of Silk Road Medical Inc (SILK) is 7.22 times as on 26-Sep-2024, a 145 premium to its peers’ median range of 2.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2023
|
-8.60
|
3.17
|
|
2022
|
-34.26
|
12.13
|
|
2021
|
-29.54
|
18.78
|
|
2020
|
-42.59
|
19.96
|
|
2019
|
-22.38
|
17.46
|
The 52-week high and low of Silk Road Medical Inc (SILK) are Rs -- and Rs -- as of 05-Apr-2026.
Silk Road Medical Inc (SILK) has a market capitalisation of $ 1,117 Mln as on 26-Sep-2024. As per SEBI classification, it is a Small Cap company.
Before investing in Silk Road Medical Inc (SILK), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.